middle.news

Radiopharm Theranostics Accelerates Trials with FDA Fast Track and Strong Cash Position

10:13am on Tuesday 29th of July, 2025 AEST Healthcare
Read Story

Radiopharm Theranostics Accelerates Trials with FDA Fast Track and Strong Cash Position

10:13am on Tuesday 29th of July, 2025 AEST
Key Points
  • FDA grants Fast Track designation for RAD101 brain metastases diagnostic
  • Dose escalation approved for RAD204 to 60mCi Lutetium-177
  • Phase 1 HEAT trial of RAD202 underway for HER2-positive tumors
  • Supply agreements secured for key radioisotopes including Lutetium-177 and Terbium-161
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE